GSA Capital Partners’s CG Oncology CGON Stock Holding History

GSA Capital Partners’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,977	Closed	-$207K	–	1771
2025 Q4	$207K	Buy	+4,977	New	+$206K	0.02%	1392

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's CGON Position: Q1 2026 in Review

GSA Capital Partners sold out of CG Oncology (CGON) in Q1 2026, closing a stake of 4,977 shares — an estimated $207K sold.

GSA Capital Partners first reported a position in CGON in Q4 2025 and held it in 1 quarter. The position peaked at $207K in Q4 2025. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

GSA Capital Partners reported no remaining CG Oncology position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 4,977 CG Oncology shares in Q1 2026, an estimated $207K.
GSA Capital Partners first reported a position in CG Oncology in Q4 2025 and held it in 1 quarter.
GSA Capital Partners's CG Oncology position peaked at $207K in Q4 2025.
233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.